Citations (51)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Yue Fang, Zhichao Yuan, Hao Zhang, Peng Wang & Jiqing Hao. (2023) Predictive Value of Serum Heat Shock Protein 90α on the Prognosis of Patients with Lung Adenocarcinoma. Journal of Inflammation Research 16, pages 1183-1193.
Read now
Read now
Sebastian Grosicki, Martyna Bednarczyk & Grażyna Janikowska. (2020) Heat shock proteins as a new, promising target of multiple myeloma therapy. Expert Review of Hematology 13:2, pages 117-126.
Read now
Read now
Jing Wang, Yun Li, Wei Sun, Jing Liu & Wenming Chen. (2018) Synergistic effects of rmhTRAIL and 17-AAG on the proliferation and apoptosis of multiple myeloma cells. Hematology 23:9, pages 620-625.
Read now
Read now
Niamh A Keane, Siobhan V Glavey, Janusz Krawczyk & Michael O’Dwyer. (2014) AKT as a therapeutic target in multiple myeloma. Expert Opinion on Therapeutic Targets 18:8, pages 897-915.
Read now
Read now
Aarthi Jayanthan, Scott C. Howard, Tanya Trippett, Terzah Horton, James A. Whitlock, Lara Daisley, Victor Lewis & Aru Narendran. (2009) Targeting the Bcl-2 family of proteins in Hodgkin lymphoma: cytotoxicity, target modulation and drug combination studies of the Bcl-2 homology 3 mimetic ABT-737. Leukemia & Lymphoma 50:7, pages 1174-1182.
Read now
Read now
Articles from other publishers (46)
Wei Chen, Guanghua Li, Jianjun Peng, Weigang Dai, Qiao Su & Yulong He. (2019) Transcriptomic analysis reveals that heat shock protein 90α is a potential diagnostic and prognostic biomarker for cancer. European Journal of Cancer Prevention 29:4, pages 357-364.
Crossref
Crossref
Sona Talaei, Hassan Mellatyar, Asadollah Asadi, Abolfazl Akbarzadeh, Roghayeh Sheervalilou & Nosratollah Zarghami. (2019)
Spotlight on 17‐
AAG
as an Hsp90 inhibitor for molecular targeted cancer treatment
. Chemical Biology & Drug Design 93:5, pages 760-786.
Crossref
Crossref
Vijay P. Kale, Sangita Phadtare, Shantu G. Amin & Manoj K. Pandey. 2019. Heat Shock Proteins in Signaling Pathways. Heat Shock Proteins in Signaling Pathways
233
251
.
Cheryl A. London, Jaime Acquaviva, Donald L. Smith, Manuel Sequeira, Luisa Shin Ogawa, Heather L. Gardner, Louis Feo Bernabe, Misty D. Bear, Sandra A. Bechtel & David A. Proia. (2018) Consecutive Day HSP90 Inhibitor Administration Improves Efficacy in Murine Models of KIT-Driven Malignancies and Canine Mast Cell Tumors. Clinical Cancer Research 24:24, pages 6396-6407.
Crossref
Crossref
Nicholas Nikesitch, James M Lee, Silvia Ling & Tara Laurine Roberts. (2018) Endoplasmic reticulum stress in the development of multiple myeloma and drug resistance. Clinical & Translational Immunology 7:1, pages e1007.
Crossref
Crossref
Katharina Blatt, Harald Herrmann, Gabriele Stefanzl, Wolfgang R. Sperr & Peter Valent. (2016)
Evaluation of
in vitro
effects of various targeted drugs on plasma cells and putative neoplastic stem cells in patients with multiple myeloma
. Oncotarget 7:40, pages 65627-65642.
Crossref
Crossref
Marta Podgórniak, Joanna Zaleska & Krzysztof Giannopoulos. (2015) Peptide-based immunotherapy in multiple myeloma. Acta Haematologica Polonica 46:3, pages 248-253.
Crossref
Crossref
Cinzia Fionda, Alessandra Soriani, Alessandra Zingoni, Angela Santoni & Marco Cippitelli. (2015) NKG2D and DNAM-1 Ligands: Molecular Targets for NK Cell-Mediated Immunotherapeutic Intervention in Multiple Myeloma. BioMed Research International 2015, pages 1-9.
Crossref
Crossref
Zuzana Sol�rov�, J�n Mojžiš & Peter Sol�r. (2014) Hsp90 inhibitor as a sensitizer of cancer cells to different therapies (Review). International Journal of Oncology.
Crossref
Crossref
Rong Li, Jianfei Qian, Wenhao Zhang, Weijun Fu, Juan Du, Hua Jiang, Hui Zhang, Chunyang Zhang, Hao Xi, Qing Yi & Jian Hou. (2014) Human heat shock protein-specific cytotoxic T lymphocytes display potent antitumour immunity in multiple myeloma. British Journal of Haematology 166:5, pages 690-701.
Crossref
Crossref
Xue Du, Yongmei Li, Xu Jing & Lina Zhao. (2014) Effect of a heat shock protein 90‑specific inhibitor on the proliferation and apoptosis induced by VEGF‑C in cervical cancer cells. Experimental and Therapeutic Medicine.
Crossref
Crossref
Nuozhou Wang, Patrick Bartlow, Qin Ouyang & Xiang-Qun Xie. (2014) Recent advances in antimultiple myeloma drug development. Pharmaceutical Patent Analyst 3:3, pages 261-277.
Crossref
Crossref
Jahangir Abdi, Guoan Chen & Hong Chang. (2013) Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms. Oncotarget 4:12, pages 2186-2207.
Crossref
Crossref
H. Direskeneli. (2013) Innate and Adaptive Responses to Heat Shock Proteins in Behcet’s Disease. Genetics Research International 2013, pages 1-6.
Crossref
Crossref
E J Born, S V Hartman & S A Holstein. (2013) Targeting HSP90 and monoclonal protein trafficking modulates the unfolded protein response, chaperone regulation and apoptosis in myeloma cells. Blood Cancer Journal 3:12, pages e167-e167.
Crossref
Crossref
Lisa Vincenz, Richard Jäger, Michael O'Dwyer & Afshin Samali. (2013) Endoplasmic Reticulum Stress and the Unfolded Protein Response: Targeting the Achilles Heel of Multiple Myeloma. Molecular Cancer Therapeutics 12:6, pages 831-843.
Crossref
Crossref
Yilin Zhao, Zheng-Jie Huang, Milladur Rahman, Qi Luo & Henrik Thorlacius. (2013) Radicicol, an Hsp90 inhibitor, inhibits intestinal inflammation and leakage in abdominal sepsis. Journal of Surgical Research 182:2, pages 312-318.
Crossref
Crossref
Huiqiong Lin, Iryna Kolosenko, Ann-Charlotte Björklund, Darya Protsyuk, Anders Österborg, Dan Grandér & Katja Pokrovskaja Tamm. (2013) An activated JAK/STAT3 pathway and CD45 expression are associated with sensitivity to Hsp90 inhibitors in multiple myeloma. Experimental Cell Research 319:5, pages 600-611.
Crossref
Crossref
Christoph J. Heuck, Sarah K. Johnson, Qing Zhang & John D. ShaughnessyJr.Jr.. 2013. Genetic and Molecular Epidemiology of Multiple Myeloma. Genetic and Molecular Epidemiology of Multiple Myeloma
17
41
.
Brian Van Ness. 2013. Neoplastic Diseases of the Blood. Neoplastic Diseases of the Blood
601
613
.
Marica Peron, Paolo Bonvini & Angelo Rosolen. (2012) Effect of inhibition of the Ubiquitin-Proteasome System and Hsp90 on growth and survival of Rhabdomyosarcoma cells in vitro. BMC Cancer 12:1.
Crossref
Crossref
T Ishii, T Seike, T Nakashima, S Juliger, L Maharaj, S Soga, S Akinaga, J Cavenagh, S Joel & Y Shiotsu. (2012) Anti-tumor activity against multiple myeloma by combination of KW-2478, an Hsp90 inhibitor, with bortezomib. Blood Cancer Journal 2:4, pages e68-e68.
Crossref
Crossref
Sarah K. Johnson, Christoph J. Heuck, Anthony P. Albino, Pingping Qu, Qing Zhang, Bart Barlogie & John D. ShaughnessyJr.Jr.. (2011) The use of molecular-based risk stratification and pharmacogenomics for outcome prediction and personalized therapeutic management of multiple myeloma. International Journal of Hematology 94:4, pages 321-333.
Crossref
Crossref
Paul G. Richardson, Asher A. Chanan-Khan, Sagar Lonial, Amrita Y. Krishnan, Michael P. Carroll, Melissa Alsina, Maher Albitar, David Berman, Marianne Messina & Kenneth C. Anderson. (2011) Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study. British Journal of Haematology 153:6, pages 729-740.
Crossref
Crossref
Saad Z. Usmani & Gabriela Chiosis. (2011) HSP90 Inhibitors as Therapy for Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia 11, pages S77-S81.
Crossref
Crossref
Meletios-Athanassios Dimopoulos, Constantine S. Mitsiades, Kenneth C. Anderson & Paul G. Richardson. (2011) Tanespimycin as Antitumor Therapy. Clinical Lymphoma Myeloma and Leukemia 11:1, pages 17-22.
Crossref
Crossref
Alessandro Allegra, Emanuela Sant’Antonio, Giuseppa Penna, Andrea Alonci, Arianna D’Angelo, Sabina Russo, Antonino Cannavò, Demetrio Gerace & Caterina Musolino. (2011) Novel therapeutic strategies in multiple myeloma: role of the heat shock protein inhibitors. European Journal of Haematology 86:2, pages 93-110.
Crossref
Crossref
Paul G. Richardson, Constantine S. Mitsiades, Jacob P. Laubach, Sagar Lonial, Asher A. Chanan-Khan & Kenneth C. Anderson. (2011) Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers. British Journal of Haematology 152:4, pages 367-379.
Crossref
Crossref
Martin Kaiser, Britta Lamottke, Maren Mieth, Michael R. Jensen, Cornelia Quadt, Carlos Garcia-Echeverria, Peter Atadja, Ulrike Heider, Ivana von Metzler, Seval Türkmen & Orhan Sezer. (2010) Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma. European Journal of Haematology 84:4, pages 337-344.
Crossref
Crossref
Rodger E. TiedemannYuan Xiao ZhuJessica SchmidtHongwei Yin, Chang-Xin ShiQiang Que, Gargi Basu, David Azorsa, Louise M. Perkins, Esteban BraggioRafael FonsecaP. Leif BergsagelSpyro Mousses & A. Keith Stewart. (2010) Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6. Blood 115:8, pages 1594-1604.
Crossref
Crossref
Marco A. Biamonte, Ryan Van de Water, Joseph W. Arndt, Robert H. Scannevin, Daniel Perret & Wen-Cherng Lee. (2009) Heat Shock Protein 90: Inhibitors in Clinical Trials. Journal of Medicinal Chemistry 53:1, pages 3-17.
Crossref
Crossref
P Wu, Y Tian, G Chen, B Wang, L Gui, L Xi, X Ma, Y Fang, T Zhu, D Wang, L Meng, G Xu, S Wang, D Ma & J Zhou. (2009) Ubiquitin B: an essential mediator of trichostatin A-induced tumor-selective killing in human cancer cells. Cell Death & Differentiation 17:1, pages 109-118.
Crossref
Crossref
J P Laubach, A Mahindra, C S Mitsiades, R L Schlossman, N C Munshi, I M Ghobrial, N Carreau, T Hideshima, K C Anderson & P G Richardson. (2009) The use of novel agents in the treatment of relapsed and refractory multiple myeloma. Leukemia 23:12, pages 2222-2232.
Crossref
Crossref
Y Zhou, B Barlogie & J D Shaughnessy. (2009) The molecular characterization and clinical management of multiple myeloma in the post-genome era. Leukemia 23:11, pages 1941-1956.
Crossref
Crossref
Cinzia Fionda, Alessandra Soriani, Giulia Malgarini, Maria Luisa Iannitto, Angela Santoni & Marco Cippitelli. (2009) Heat Shock Protein-90 Inhibitors Increase MHC Class I-Related Chain A and B Ligand Expression on Multiple Myeloma Cells and Their Ability to Trigger NK Cell Degranulation. The Journal of Immunology 183:7, pages 4385-4394.
Crossref
Crossref
Constantine S. Mitsiades, Teru Hideshima, Dharminder Chauhan, Douglas W. McMillin, Steffen Klippel, Jacob P. Laubach, Nikhil C. Munshi, Kenneth C. Anderson & Paul G. Richardson. (2009) Emerging Treatments for Multiple Myeloma: Beyond Immunomodulatory Drugs and Bortezomib. Seminars in Hematology 46:2, pages 166-175.
Crossref
Crossref
Efstathios Kastritis, Andreas Charidimou, Andreas Varkaris & Meletios A. Dimopoulos. (2009) Targeted therapies in multiple myeloma. Targeted Oncology 4:1, pages 23-36.
Crossref
Crossref
Tzu-Yin Lin, Misty Bear, Zhenjian Du, Kevin P. Foley, Weiwen Ying, James Barsoum & Cheryl London. (2008) The novel HSP90 inhibitor STA-9090 exhibits activity against Kit-dependent and -independent malignant mast cell tumors. Experimental Hematology 36:10, pages 1266-1277.
Crossref
Crossref
James R Berenson & Ori Yellin. (2008) New drugs in multiple myeloma. Current Opinion in Supportive and Palliative Care 2:3, pages 204-210.
Crossref
Crossref
T Stühmer, A Zöllinger, D Siegmund, M Chatterjee, E Grella, S Knop, M Kortüm, C Unzicker, M R Jensen, C Quadt, P Chène, J Schoepfer, C García-Echeverría, H Einsele, H Wajant & R C Bargou. (2008) Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma. Leukemia 22:8, pages 1604-1612.
Crossref
Crossref
Alissa Huston, Xavier Leleu, Xiaoying Jia, Anne-Sophie Moreau, Hai T. Ngo, Judith Runnels, Judy Anderson, Yazan Alsayed, Aldo Roccaro, Sonia Vallet, Evdoxia Hatjiharissi, Yu-Tsu Tai, Peter Sportelli, Nikhil Munshi, Paul Richardson, Teru Hideshima, David G. Roodman, Kenneth C. Anderson & Irene M. Ghobrial. (2008) Targeting Akt and Heat Shock Protein 90 Produces Synergistic Multiple Myeloma Cell Cytotoxicity in the Bone Marrow Microenvironment. Clinical Cancer Research 14:3, pages 865-874.
Crossref
Crossref
Paul N. Meyer, Shantanu Roychowdhury, Ameet R. Kini & Serhan Alkan. (2008) HSP90 inhibitor 17AAG causes apoptosis in ATRA-resistant acute promyelocytic leukemia cells. Leukemia Research 32:1, pages 143-149.
Crossref
Crossref
Constantine S. Mitsiades, Teru Hideshima, Nikhil C. Munshi, Paul G. Richardson & Kenneth C. Anderson. 2009. Myeloma Therapy. Myeloma Therapy
291
308
.
Constantine S. Mitsiades, Patrick J. Hayden, Kenneth C. Anderson & Paul G. Richardson. (2007) From the bench to the bedside: emerging new treatments in multiple myeloma. Best Practice & Research Clinical Haematology 20:4, pages 797-816.
Crossref
Crossref
YK Jeon, CH Park, K‐Y Kim, YC Li, J Kim, YA Kim, J‐H Paik, B‐K Park, C‐W Kim & Y‐N Kim. (2007) The heat‐shock protein 90 inhibitor, geldanamycin, induces apoptotic cell death in Epstein–Barr virus‐positive NK/T‐cell lymphoma by Akt down‐regulation. The Journal of Pathology 213:2, pages 170-179.
Crossref
Crossref
Jens R. Sydor, Emmanuel Normant, Christine S. Pien, James R. Porter, Jie Ge, Louis Grenier, Roger H. Pak, Janid A. Ali, Marlene S. Dembski, Jebecka Hudak, Jon Patterson, Courtney Penders, Melissa Pink, Margaret A. Read, Jim Sang, Caroline Woodward, Yilong Zhang, David S. Grayzel, Jim Wright, John A. Barrett, Vito J. Palombella, Julian Adams & Jeffrey K. Tong. (2006) Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90. Proceedings of the National Academy of Sciences 103:46, pages 17408-17413.
Crossref
Crossref